Highlights

  • Revenue increased 10.7% to AUD 3.32 bn.
  • Underlying EBIT rose 19.3% to AUD 599.0 mn.
  • Underlying net profit after tax grew 25.8% to AUD 381.2 mn.
  • Underlying EBIT Margin increased 129 basis points to 18.0%.

ALS Limited (ASX:ALQ) shares traded at AUD 20.62 on 17 November 2026, down 3.01%, with 896,826 shares changing hands. ALS reported higher full-year Revenue and Underlying Profit as strong Commodities growth supported the laboratory testing group. Results in Life Sciences varied by service line and market.

Company Overview

ALS supplies testing and analytical services across Commodities and Life Sciences. Minerals testing depends on sample activity from explorers and producers. Its Life Sciences businesses address different markets, including food, environmental and pharmaceutical testing.

Annual Result

Commodities revenue increased 18.8% to AUD 1.294 bn and its underlying EBIT reached AUD 381.5 mn. In Life Sciences, food testing recorded 7.2% organic growth. ALS also described softer environmental activity in the Americas and the end of a two-year transformation program at Nuvisan.

Sector Context

Test volumes reflect the number of samples and types of methods customers order. The work can come from large producers or smaller exploration companies. Growth may require capacity in the appropriate laboratories as well as specialist staff and equipment.

Risks to Watch

The Business must manage sample throughput, quality and operating costs across markets. The group reported that some environmental work was deferred. Conditions by end market and the product mix can affect the extent to which higher volumes translate into margin.